MGTX — MeiraGTx Holdings plc

—
Nasdaq · Health Care · Biotechnology · CIK 1735438 ·
Last close
$8.46
Market Cap
$826.80M
52W High
$15.35
52W Low
$6.62
ADV30
747,908
Next earnings
2026-11-12
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 4,814,000 1,391,000 -49,878,000 -51,212,000 411,695,000 184,650,000 196,474,000
Jun 2026 321,434,000 314,270,000 244,425,000 160,720,000 396,449,000 143,166,000 180,668,000
Mar 2026 293,000 95,000 -40,817,000 -46,313,000 244,655,000 71,541,000 302,785,000
Dec 2025 75,364,000 74,888,000 26,472,000 15,088,000 244,430,000 65,931,000 250,223,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,419,000
Investing CF
$-28,715,000
Financing CF
$196,883,000
CapEx
$-28,982,000
Dividends Paid
—
Buybacks
$-18,193,000
EPS Diluted TTM
$-0.01
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-753,028,000
Inventory
$0
Receivables
$29,560,000
ST Investments
—
EBIT TTM
$91,340,000
Pretax Income TTM
$81,138,000
Interest Exp TTM
$12,477,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$401,904,992
EBITDA
$191,996,992
Free Cash Flow
$47,396,624
Enterprise Value
$846,507,328
Total Cash
$184,650,000
Total Debt
$133,851,000
Shares Out
97,730,540
Trailing EPS
$0.87
Book Value
$2.29
ROE
89.5%
ROA
37.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 81,391,000 -105,968,000 -114,201,000 244,430,000 250,223,000 -5,793,000 -46,359,000
Dec 2024 33,279,000 -164,212,000 -147,791,000 269,751,000 201,924,000 67,827,000 -104,495,000
Dec 2023 14,017,000 -137,061,000 -84,027,000 326,744,000 188,567,000 138,177,000 -105,365,000
Dec 2022 15,920,000 -116,355,000 -129,615,000 318,237,000 200,499,000 117,738,000 -73,098,000

TTM Snapshot

Revenues TTM
$398,456,000
NetIncome TTM
$78,982,000
OpCashFlow TTM
—
Assets (Latest)
$396,449,000
Forward EPS
$-1.52

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $7.50 · spot: $8.32 · call volume: 89 · put volume: 15

Peers — same industry

TickerNameMarket CapLastDaily %
BBTX Bambusa Therapeutics, Inc. $832.91M $16.35 —
PRME Prime Medicine, Inc. $854.20M $3.84 —
GLUE Monte Rosa Therapeutics, Inc. $775.03M $9.07 —
AURA Aura Biosciences, Inc. $744.13M $7.15 —
ODTX Odyssey Therapeutics, Inc. $931.07M $19.37 —

News headlines (Yahoo Finance, 1h cache)

MeiraGTx Announces Oral Presentation at ObesityWeek 2026
2026-11-16 12:00 · Yahoo
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates
2026-11-12 13:15 · Yahoo
MeiraGTx Reports Third Quarter 2026 Financial and Operational Results
2026-11-12 13:00 · Yahoo
MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
2026-10-27 12:00 · Yahoo
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
2026-09-23 12:00 · Yahoo
What Could MeiraGTx Holdings (MGTX) New Hires And Profit Swing Signal?
2026-08-14 23:12 · Yahoo
MeiraGTx Seen Nearing First Commercial Launches as Key Programs Advance, RBC Says
2026-08-14 16:02 · Yahoo
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
2026-08-13 13:25 · Yahoo
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-06 20:30 · Yahoo
Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
2026-07-15 13:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.